Journal of Infectious Diseases and Immunity
Subscribe to JIDI
Full Name*
Email Address*

Article Number - F7BBC0656012

Vol.10(1), pp. 1-7 , January 2018
ISSN: 2141-2375

 Total Views: 0
 Downloaded: 0

Full Length Research Paper

Immunological outcomes of neverapin (NVP) versus efafrenz (EFV) based antiretroviral therapy (ART) regimen among children on ART: A study from Black Lion Hospital, Addis Ababa, Ethiopia

Abebe Sorsa
  • Abebe Sorsa
  • Asella College of Health Science, Arsi University, Asella, Ethiopia.
  • Google Scholar

 Received: 07 December 2017  Accepted: 25 January 2018  Published: 31 January 2018

Copyright © 2018 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0

Antiretroviral therapy has reduced HIV-related morbidity and mortality substantially. WHO recommends the use of Nevirapine or Efavirenz as first line combined with two from nucleoside reverse transcriptase inhibitors. In this study the immunological outcomes of Neverapin versus Efafrenz based ART was assessed. Medical records of patients were retrieved and important variables were captured to standard questionnaire. Medical records of 120 patients from NVP-based regimen and 60 patients from EFV groups were revised. The CD4 cell count at the start of HAART ranged from 3-2003 cell/ml with an inter quartile range (IQR) of 231-317 cell/ml among NVP group. And among patients taking EFV based ART regimen, baseline CD4 count ranged 13-2095 cell/ml with an IQR range of 250-345 cell/ml. After six months of HAART, the CD4 cell count of  NVP based regimen range from 71-2300 c/ml with IQR of 458-612 c/ml, and mean CD4 cell count difference of 215, 95% CI (175.414-245.613). From EFV based group, CD4 count ranged from 65-2100 c/ml with IQR of 435-605 c/ml, and the mean CD4 cell count difference of 205, 95% CI (155.404-235.623).  The immunological recovery was found to be comparable among the two groups. Advanced clinical stage of the disease, severe immune suppression, presence of anemia, presence of chronic diarrhea , poor weight gain during first six months of ART were adversely affected the trends of CD4 recovery. This research report demonstrated that immunological outcomes were comparable among patient taking NVP vs EFV based ART regimen.
Key words: Immunologic outcomes, HIV/AIDS; HAART/ART, nevirapine (NVP), efavirenz (EFV).


AIDS, Acquired immunodeficiency syndrome; ART, antiretroviral treatment;  HAART, highly active antiretroviral therapy; HIV, human immune-virus; MTCT, mother to child transmission; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PMTCT, prevention of mother to child transmission; SD, standard deviation; TB, tuberculosis; WHO, World Health Organization.

Abebe S (2017). Predictors of Sub-Optimal CD4 Recovery during the First Six Months of Anti-Retroviral Treatment (ART) in HIV Infected Children: A Retrospective Cross Sectional Study from Tikur Anbessa Tertiary Hospital, Addis Ababa, Ethiopia. J. Blood Lymph 7(3). Available at: 



Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, Balkan S, Olson D, Olaro C, Pujades-Rodríguez M (2009). Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC. Infect. Dis. 9(1):81.


Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F (2015). CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. PLoS One 10(3):e0122583.


Bacha T, Tilahun B, Worku A (2012). Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infec. Dis. 12(197).


Brian CZ, Phungula T, Zanoni HM, France H, Cook EF, Feeney ME (2012). Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa. PLoS One 7(3):e33611.


Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Bernardi S, Viganò A, Guarino A, Giaquinto C, Esposito S, Badolato R (2009). Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC. Infect. Dis. 9(140).


Crum-Cianflone NF, Roediger M, Eberly LE, Ganesan A, Weintrob A, Johnson E, Agan BK, Infectious Disease Clinical Research Program HIV Working Group (2011). Impact of Weight on Immune Cell Counts among HIV-Infected Persons. Clin. Vaccine Immunol. 18(6):940-946.


de Castilla DL, Verdonck K, Otero L, Iglesias D, Echevarría J, Lut L, Gotuzzo E, Seas C (2008). Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int. J. Infect. Dis. 12:325-331.


Diniz LMO, Maia MMM, Camargos LS, Amaral LC, Goulart EMA, Pinto JA (2011). Impact of HAART on growth and hospitalization rates among HIV-infected children. J. Pediatr. 87:131-137.


Doris MM, Wu AW, Martin F, Katamba A, Seeley J (2015). Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study. BMC Heal. Ser. Res. 15 (292).


Eshun-Wilson I, Taljaard JJ, Nachega JB (2012). Sub-optimal CD4 T-lymphocyte responses among HIV infected patients who develop TB during the first year of ART. J. AIDS Clin. Res. 3(1).


Ethiopia Ministry of Health (2012). Guidelines for Pediatric HIV/AIDS Care and Treatment in Ethiopia.1st ed.


Gezie LD (2016). Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. BMC Res Note 9(377).


Hai-Yin J, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B (2014). Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Int. J. Infect. Dis. 25:130-135.


Junwen Z, Dongchi Z (2014). Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China. BMC Res. Note 7(419).


Kate S, Brennan AT, Maskew M, Long L, Berhanu R, Sanne I, Fox MP (2014). The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J. Int. AIDS Soc. 17 (19065).


Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M (2005). Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/mL in HIV Type 1–Infected Individuals Receiving Potent Antiretroviral Therapy. Clin. Infect. Dis. 41(3):361-372.


Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K (2008). Efficacy and tolerability of nevirapine-versus efavirenz-containing regimens in HIV-infected Thai children. Int. J. Infect. Dis. 12(6):e33-e38.


Madec Y, Szumilin E, Genevier C, Ferradini L, Balkan S, Pujades M, Fontanet A (2009). Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. Aids 23(7):853-861.


Mihiretu MK, Desalegn TZ Berihun MZ (2014). Predictors of CD4 Count Changes after Initiation of Antiretroviral Treatment in university of Gondar Hospital, Gondar in Ethiopia. Clin. Res. HIV/ AIDS. 2(2).


Ojha CR, Shakya G, Dumre SP (2016). Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal. Hind. BioMed. Res. Int. 10(7).


Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V (2009). Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy. Pediatr. Infect. Dis. J. 28:488-492.


Reda AA, Biadgilign S, Deribew A, Gebre B, Deribe K (2013). Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: A retrospective longitudinal study. PLoS One 8(4):e58595.


Tadesse A, Worku A, Kebede Y, Alemu K, Kasim A, Shkedy Z (2017). Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies. Sys. Rev. 6(173).


Theophilus BK, Owusu M, Mutocheluh M, Nguah SB, Obeng-Baah J, Hanson C, Dompreh A. (2015). Pattern and predictors of immunologic recovery in HIV infected patients. BMC Res. Notes 8(1):413.


Yotebieng M, Van Rie A, Moultrie H, Meyers T (2010). Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS 24(1):139-146.


Zanoni BC, Thuli P, Holly M, Zanoni, Holly F (2012). Predictors of Poor CD4 and Weight Recovery in HIV-Infected Children Initiating ART in South Africa, Johannesberg: Minuteman press.



APA Sorsa, A. (2018). Immunological outcomes of neverapin (NVP) versus efafrenz (EFV) based antiretroviral therapy (ART) regimen among children on ART: A study from Black Lion Hospital, Addis Ababa, Ethiopia. Journal of Infectious Diseases and Immunity, 10(1), 1-7.
Chicago Abebe Sorsa. "Immunological outcomes of neverapin (NVP) versus efafrenz (EFV) based antiretroviral therapy (ART) regimen among children on ART: A study from Black Lion Hospital, Addis Ababa, Ethiopia." Journal of Infectious Diseases and Immunity 10, no. 1 (2018): 1-7.
MLA Abebe Sorsa. "Immunological outcomes of neverapin (NVP) versus efafrenz (EFV) based antiretroviral therapy (ART) regimen among children on ART: A study from Black Lion Hospital, Addis Ababa, Ethiopia." Journal of Infectious Diseases and Immunity 10.1 (2018): 1-7.

Subscription Form